EASD 2025 15 - 19 September 2025

Comparative Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide on Cardiovascular Outcomes in US Medicare Beneficiaries With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Authors :

Xi Tan, PhD, PharmD¹; Joanna Harton, PhD²; Yuanjie Liang, MS¹; Lin Xie, MS¹; Cynthia Gutierrez, MPH²; Chalak Muhammad, MD¹; Caroline Swift, PhD¹

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Semaglutide

RWE HEOR